JaLCDOI 10.18926/AMO/57379
FullText URL 73_5_469.pdf
Author Yamasaki, Satoshi| Kada, Akiko| Nagai, Hirokazu| Yoshida, Isao| Choi, Ilseung| Saito, Akiko M.| Iwasakia, Hiromi|
Abstract Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. Romidepsin was launched in Japan as a consolidation therapy agent after conventional salvage chemotherapy with gemcitabine, dexamethasone, and cisplatin (GDP). GDP therapy will be administered every 3 weeks. If complete response, partial response, or stable disease is confirmed after 2-4 GDP cycles, romidepsin will be administered every 4 weeks. The primary endpoint is a 2-year progression-free survival rate. Patients participating in this study and undergoing treatment can expect results similar to or better than those of conventional therapies.
Keywords peripheral T-cell lymphoma not otherwise specified angioimmunoblastic T-cell lymphoma gemcitabine cisplatin, romidepsin
Amo Type Clinical Study Protocol
Published Date 2019-10
Publication Title Acta Medica Okayama
Volume volume73
Issue issue5
Publisher Okayama University Medical School
Start Page 469
End Page 474
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 31649375
Web of Sience KeyUT 000491886600014
FullText URL Blood advances 2018.pdf
Author Inamoto, Yoshihiro| Matsuda, Tomohiro| Tabuchi, Ken| Kurosawa, Saiko| Nakasone, Hideki| Nishimori, Hisakazu| Yamasaki, Satoshi| Doki, Noriko| Iwato, Koji| Mori, Takehiko| Takahashi, Satoshi| Yabe, Hiromasa| Kohno, Akio| Nakamae, Hirohisa| Sakura, Toru| Hashimoto, Hisako| Sugita, Junichi| Ago, Hiroatsu| Fukuda, Takahiro| Ichinohe, Tatsuo| Atsuta, Yoshiko| Yamashita, Takuya| Japan Society for Hematopoietic Cell Transplantation Late Effects and Quality of Life Working Group|
Published Date 2018-08
Publication Title Blood Advances
Volume volume2
Issue issue15
Publisher American Society of Hematology
Start Page 1901
End Page 1903
ISSN 2473-9529
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
File Version publisher
PubMed ID 30087108
DOI 10.1182/bloodadvances.2018020966
Related Url isVersionOf https://doi.org/10.1182/bloodadvances.2018020966
Author Okazaki, Hiroyuki| Yoshida, Rikiya| Muro, Takayuki| Nakamura, Tetsuya| Wakita, Takanori| Muraoka, Yuji| Hirai, Masaaki| Kato, Hiromitsu| Yamasaki, Satoshi| Takano, Yoshihiko| Ishii, Satoshi| Oguchi, Tamio| Yokoya, Takayoshi|
Published Date 2011-02-21
Publication Title Applied Physics Letters
Volume volume98
Issue issue8
Content Type Journal Article
Author Taguchi, Hideki| Yamasaki, Satoshi| Itadani, Atsushi| Yosinaga, Masashi| Hirota, Ken|
Published Date 2008-05-15
Publication Title Catalysis Communications
Volume volume9
Issue issue9
Content Type Journal Article
JaLCDOI 10.18926/AMO/32661
FullText URL fulltext.pdf
Author Marutani, Morio| Kusachi, Shouzo| Kajikawa, Yutaka| Yamasaki, Satoshi| Tsuji, Takao|
Abstract <p>To test the hypothesis that the endothelium-derived relaxing factor (EDRF) contributes to coronary vasodilation induced by myocardial ischemia, we examined the effect of NG-nitro-L-arginine (a potent and selective inhibitor of EDRF release) on the coronary reactive hyperemic response in the open-chest dogs. Intracoronary infusion of NG-nitro-L-arginine at a coronary plasma concentration of 5 x 10(-5) M had no effect on hemodynamics and myocardial oxygen metabolism, but attenuated repayment of the flow debt by an average of 20.4% and 20.0% following coronary occlusion for 10 sec and 20 sec, respectively. Concomitant infusion of NG-nitro-L-arginine at the same concentration and 8-phenyltheophylline (a potent adenosine receptor blocker) at a coronary plasma concentration of 10(-5) M further attenuated flow debt repayment following 10 sec and 20 sec of coronary occlusion by 47.7 and 59.4%, respectively. These results indicate that EDRF plays a significant role in the coronary reactive hyperemic response and may cause vasodilation independently of adenosine-mediated vasodilation following coronary occlusion.</p>
Keywords myocardial reactive hyperemia nitric oxide amino acids metabolic vasodilation
Amo Type Article
Published Date 1992-10
Publication Title Acta Medica Okayama
Volume volume46
Issue issue5
Publisher Okayama University Medical School
Start Page 337
End Page 343
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 1442155
Web of Science KeyUT A1992JX49500004